|
|
|
| Expression level of PD-L1 in clinicopathological specimens of oral cancer#br# |
| MENG Qingwei |
| Department of Stomatology, Beijing Huairou Hospital, Beijing 101400, China |
|
|
|
Abstract Objective To investigate the expression of programmed death ligand-1 (PD-1) protein in the pathological tissues of oral cancer, such as oropharyngeal cancer, maxillary sinus cancer and tongue cancer, etc. Methods From January 2015 to January 2020, 20 pathological tissues diagnosed with oral cancer were collected from Beijing Huairou Hospital, and their paraffin sections were stained with PD-L1 by immunohistochemistry method. All sections were photographed in 10 tissue regions randomly selected under an optical microscope, and the proportion of positive cells was calculated and the average value was taken. The positive grade of PD-L1 was qualitatively analyzed according to the evaluation criteria. Results Among the 20 cases of oral cancer pathological tissues collected in this study, six cases (30%) showed strong positive expression of PD-L1, four cases (20%) showed moderate positive expression of PD-L1, four cases (20%) showed weak positive expression of PD-L1, and six cases (30%) showed negative expression of PD-L1. A total of 14 cases (70%) showed positive expression of PD-L1. Conclusion The pathogenesis of oropharyngeal cancer, maxillary sinus cancer, tongue cancer and other oral cancers may also be caused by immune escape caused by high expression of PD-L1 in tumor cells.
|
|
|
|
|
|
[1] Zhang SK，Zheng R，Chen Q，et al. Oral cancer incidence and mortality in China，2011 [J]. Chin J Cancer Res，2015， 27（1）：44-51.
[2] Kalra H，Drummen GP，Mathivanan S. Focus on Extracel lular Vesicles：Introducing the Next Small Big Thing [J]. Int J Mol Sci，2016，17（2）：170.
[3] Lee CK，Man J Lord S，et al. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A MetaAnalysis [J]. J Thorac Oncol，2017，12（2）：403-407.
[4] 施敬瑶，张海洋，陈公琰.PD-1/ PD-L1信号通路在实体瘤中的研究进展[J].中国医药导报，2015，12（10）：47-50.
[5] Carbone DP，Reck M，Paz-Ares L，et al. First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer [J]. N Engl J Med，2017，376（25）：2415-2426.
[6] Torlakovic EE，Nielsen S，Francis G，et al. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee [J]. Appl Immunohistochem Mol Morphol，2015， 23（1）：1-18.
[7] Hirsch FR，MeElhinny A，Stanforth D，et al. PD-L1 Immunohistochemistry assays for lung cancer： results from phase 1 of the“blueprint PD-L1 IHC assay comparison project” [J]. J Thorac Oncol，2017，12（2）：208-222.
[8] Lisberg A，Cummings A，Goldman JW，et al. A Phase Ⅱ Study of Pembrolizumab in EGFR-Mutant，PD-L1+，Tyrosine Kinase Inhibitor（TKI）Naive Patients with Advanced NSCLC [J]. J Thorac Oncol，2018，13（8）：1138-1145.
[9] Jiang D，Song Q，Wang H，et al. Independent prognostic role of PD-Ll expression in patients with esophageal squamous cell carcinoma [J]. Oncotarget，2017，8（5）：8315-8329.
[10] Seyedin SN，Hasibuzzaman MM，Pham V，et al. Combinationtherapy with radiation and PARP inhibition enhancesresponsiveness to anti-PD-1 therapy in colorectal tumor models [J]. Int J Radiat Oncol，2020，108（1）： 81-92.
[11] Yuan W，Deng D，Jiang H，et al. Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1therapy in microsatellite instability colorectal cancer[J]. CancerImmunol Immunother，2019，68（2）： 257-268.
[12] 胡淼，刘秋燕.限制免疫检查点阻断疗效的关键因素及联合抗肿瘤对策的研究进展[J].中国肿瘤生物治疗杂志，2019，26 （9）：933-940.
[13] Curdy N，Lanvin O，Laurent C，et al. Regulatory mechanisms of inhibitory immune checkpoint receptors expression [J]. Trends Cell Biol，2019，29（10）：777-790.
[14] Masuda T，Noda M，Kitagawa A，et al. The expressionlevel of PD-L1（CD274）mRNA in peripheral blood is a potential biomarker for predicting recurrence in breast cancer [J]. Anticancer Res，2020，40（7）：3733-3742.
[15] Callahan MK，Wolchok JD. Recruit or reboot? How doesanti-PD-1 therapy change tumor-infiltrating lymphocytes? [J]. Cancer Cell，2019，36（3）： 215-217.
[16] Kamada T，Togashi Y，Tay C，et al. PD-1+regulatory Tcells amplified by PD-1 blockade promote hyperprogression ofcancer[J]. Proc Natl Acad Sci U S A，2019，116（20）：9999-10008.
[17] Fan Y，Che X，Qu J，et al. Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis[J]. Ann Surg Oncol，2019，26（11）：3745-3755.
[18] Li Y，Cui X，Yang YJ，et al. Serum sPD-1 and sPD-L1 as biomarkers for evaluating the efficacy of neoadjuvant chemotherapy in triplenegative breast cancer patients[J]. Clin Breast Cancer，2019，19（5）：326-332.
[19] Chen X，Ma L，Wang X，et al. Reactive capillary hemangiomas：a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210[J]. Cancer Biol Med，2019， 16（1）：173-181.
[20] Callaghan CM，Seyedin SN，Mohiuddin IH，et al. Theeffect of concurrent stereotactic body radiation and anti-PD-1therapy for recurrent metastatic sarcoma[J]. Radiat Res，2020，194（2）：124-132.
[21] Mok TSK，Wu YL，Kudaba I，et al. Pembrolizumab versuschemotherapy for previously untreated，PD-L1-expressing，locally advanced or metastatic non-small-cell lung cancer（KEYNOTE-042）：a randomised，open-label，controlled，phase3 trial [J]. Lancet，2019，393（10183）：1819-1830.
[22] Garon EB，Hellmann MD，Rizvi NA，et al. Five-year overall survival for patients with advanced non-small-cell lungcancer treated with pembrolizumab：results from the phaseI KEYNOTE-001 Study[J]. J Clin Oncol，2019，37（28）：2518-2527.
[23] Reck M，Rodríguez-Abreu D，Robinson AG，et al. Updatedanalysis of KEYNOTE-024：pembrolizumab versus platinum-based chemotherapy for advanced non-small-celllung cancer with PD-L1 tumor proportion score of 50% orgreater [J]. J Clin Oncol，2019，37（7）：537-546. |
|
|
|
